Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease

被引:18
作者
Bottini, A
Berruti, A
Tampellini, M
Morrica, B
Brunelli, A
Gnocchi, E
Brizzi, MP
Aguggini, S
Fara, E
Alquati, P
Dogliotti, L
机构
[1] AZIENDA IST OSPED,DIV RADIOTERAPIA ONCOL & MED NUCL,CREMONA,ITALY
[2] AZIENDA IST OSPED,DIV CHIRURG GEN,CREMONA,ITALY
[3] UNIV TURIN,DIPARTIMENTO SCI CLIN & BIOL,AZIENDA OSPED SAN LUIGI ORBASSANO,TURIN,ITALY
关键词
CA; 15-3; tissue polypeptide antigen; tissue polypeptide-specific antigen; mucinous-like cancer antigen; carcinoembryonic antigen; neoadjuvant chemotherapy; breast neoplasms;
D O I
10.1159/000218043
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Serum levels of CA 15-3, mucinous-like cancer antigen, carcinoembryonic antigen, tissue polypeptide antigen and tissue polypeptide-specific antigen (TPS) have been determined in 99 patients with T2-4 N0-1 M-0 breast cancer (BC) before and after primary (neoadjuvant) chemotherapy and after surgery, As a whole, no difference in marker levels was apparent according to tumor and patient characteristics, with the only exception of TPS values, which showed an inverse relationship with the histologic grade, Serum marker levels did not substantially change with respect to baseline either after chemotherapy, despite the high response rate obtained, or after surgery, These data indicate a limited contribution of the primary tumor to the serum marker levels and are consistent for the scarce usefulness of marker evaluation in BC patients with an early stage of disease, Interestingly, pretreatment elevated CA 15-3 levels were correlated with a higher recurrence rate, further supporting the prognostic significance of this tumor marker.
引用
收藏
页码:301 / 310
页数:10
相关论文
共 38 条
[1]   NEOADJUVANT CHEMOTHERAPY IN 126 OPERABLE BREAST CANCERS [J].
BELEMBAOGO, E ;
FEILLEL, V ;
CHOLLET, P ;
CURE, H ;
VERRELLE, P ;
KWIATKOWSKI, F ;
ACHARD, JL ;
LEBOUEDEC, G ;
CHASSAGNE, J ;
BIGNON, YJ ;
DELATOUR, M ;
LAFAYE, C ;
DAUPLAT, J .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (4-5) :896-900
[2]   PROGNOSTIC VALUE IN PREDICTING OVERALL SURVIVAL OF 2 MUCINOUS MARKERS - CA-15-3 AND CA-125 IN BREAST-CANCER PATIENTS AT FIRST RELAPSE OF DISEASE [J].
BERRUTI, A ;
TAMPELLINI, M ;
TORTA, M ;
BUNIVA, T ;
GORZEGNO, G ;
DOGLIOTTI, L .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (14) :2082-2084
[3]   CA-15.3 DETERMINATION IN PATIENTS WITH BREAST-CANCER - CLINICAL UTILITY FOR THE DETECTION OF DISTANT METASTASES [J].
BOMBARDIERI, E ;
PIZZICHETTA, M ;
VERONESI, P ;
SEREGNI, E ;
BOGNI, A ;
MAFFIOLI, L ;
JOTTI, GS ;
BASSETTO, MA ;
ZURRIDA, S ;
COSTA, A .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (01) :144-146
[4]   PRIMARY CHEMOTHERAPY TO AVOID MASTECTOMY IN TUMORS WITH DIAMETERS OF 3 CENTIMETERS OR MORE [J].
BONADONNA, G ;
VERONESI, U ;
BRAMBILLA, C ;
FERRARI, L ;
LUINI, A ;
GRECO, M ;
BARTOLI, C ;
DEYOLDI, GC ;
ZUCALI, R ;
RILKE, F ;
ANDREOLA, S ;
SILVESTRINI, R ;
DIFRONZO, G ;
VALAGUSSA, P .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (19) :1539-1545
[5]  
Bottini A, 1996, ANTICANCER RES, V16, P3105
[6]  
BRIFFOD M, 1989, CANCER, V63, P631, DOI 10.1002/1097-0142(19890215)63:4<631::AID-CNCR2820630405>3.0.CO
[7]  
2-W
[8]  
COLOMER R, 1989, CANCER, V64, P1674, DOI 10.1002/1097-0142(19891015)64:8<1674::AID-CNCR2820640820>3.0.CO
[9]  
2-V
[10]   THE USEFULNESS OF CA15.3, MUCIN-LIKE CARCINOMA-ASSOCIATED ANTIGEN AND CARCINOEMBRYONIC ANTIGEN IN DETERMINING THE CLINICAL COURSE IN PATIENTS WITH METASTATIC BREAST-CANCER [J].
DEPRESBRUMMER, P ;
ITZHAKI, M ;
BAKKER, PJM ;
HOEK, FJ ;
VEENHOF, KHN ;
DEWIT, R .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1995, 121 (07) :419-422